Nearly two decades have passed since a coronavirus known as SARS emerged in China, killing hundreds of people and sparking panic that sent a chill through the global economy. The virus now rampaging across China could be much more damaging.
SARS sickened 8,098 people and killed 774 before it was contained. The new coronavirus, which originated in the central Chinese city of Wuhan, has already killed more than 700 people and infected over 34,400 across 25 countries and territories. Chinese officials have locked down Wuhan and several other cities, but the virus continues to spread.
What is coronavirus?
Coronaviruses are a group of viruses that cause respiratory tract illnesses, including the common cold, but can sometimes be more serious, particularly for infants, the elderly and patients with weak or compromised immune systems, according to the US Centres for Disease Control and Prevention (CDC).
What are the coronavirus symptoms?
Unfortunately, the symptoms are similar to normal flu symptoms – including fever, a cough and shortness of breath – making them difficult to spot. The CDC noted that symptoms may emerge between two and 14 days after exposure to the virus.
How is the coronavirus transmitted?
Initially it was thought that virus was spread only through human contact with animals because the source of the outbreak was believed to be a fish and live animal market in Wuhan, Chinese authorities have confirmed that the coronavirus can also be spread through human-to-human contact.
Vaccines and drugs
The Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) is one group leading the field. It has funded three projects – one by Inovio, the second with the Australian University of Queensland and the third with Moderna, which will work with the US National Institutes of Health and National Institutes of Allergy and Infectious Diseases.
CEPI CEO Richard Hatchett commented: “Given the rapid global spread of the nCoV-2019 virus the world needs to act quickly and in unity to tackle this disease. Our intention with this work is to leverage our work on the MERS coronavirus and rapid response platforms to speed up vaccine development.
Current global spread of the virus
According to WHO data, as of 20 January, there were 282 confirmed cases of the virus, 278 of which originated in China, centred around the city of Wuhan and the surrounding region with 258 cases. Of the 278 Chinese cases, 51 people were severely ill, 12 were in a critical condition and six deaths had been reported from Wuhan.
On 13th January, Thailand reported the first imported case of 2019-nCoV from someone who had travelled to Wuhan. Within a week there was another confirmed case in Thailand, as well as one case in Japan and one in the Republic of Korea.
There were reports of further cases in Taiwan and in Australia on 21 January. On 22 January, the US CDC reported the first case of 2019-nCoV in the US, causing the benchmark S&P 500 index to slide 0.3% on the stock market, according to the Financial Times.
Between 22 and 29 January, the disease continued to spread throughout Asia – new cases emerged in Singapore, Hong Kong, Sri Lanka, Cambodia, Nepal and Malaysia. Outside of East Asia, new cases have emerged in France, Germany, the UAE and Canada. Keep up-to-date with the countries affected here.
Current status live updated in below website: https://thewuhanvirus.com

